Diffuse Large B Cell Lymphoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 54 expanded access programs, clinical trials, and compassionate use pathways listed for Diffuse Large B Cell Lymphoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with diffuse large b cell lymphoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 18 programs are currently active or recruiting, with the remaining 36 in other lifecycle stages. Sponsors actively running programs in this area include Genmab, Hoffmann-La Roche, Merck Sharp & Dohme LLC, National Cancer Institute (NCI), Barbara Ann Karmanos Cancer Institute, and others.
By recruiting status
Snapshot of where every Diffuse Large B Cell Lymphoma program currently sits in its lifecycle.
- Active / Recruiting18
- Inactive36
Top sponsors
Organisations running the most Diffuse Large B Cell Lymphoma programs in the directory.
- Genmab6 programs
- Hoffmann-La Roche3 programs
- Merck Sharp & Dohme LLC3 programs
- National Cancer Institute (NCI)3 programs
- Barbara Ann Karmanos Cancer Institute2 programs
- Incyte Corporation2 programs
- New York Medical College2 programs
- Acerta Pharma BV1 program
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1 program
- AstraZeneca1 program
Diffuse Large B Cell Lymphoma programs (54)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on Acalabrutinib Combined with R-CHOP for Untreated Non-GCB Diffuse Large B-Cell Lymphoma — Acerta Pharma BV
- Long-term Study of Ibrutinib for Ongoing Access and Safety Monitoring — Janssen Research & Development, LLC
- Phase 3 Study Comparing Epcoritamab to Chemotherapy in Patients with Difficult-to-Treat Diffuse Large B-cell Lymphoma (DLBCL) — Genmab
- Phase III Study Comparing Glofitamab with Gemcitabine and Oxaliplatin to Rituximab with Gemcitabine and Oxaliplatin for Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- Study on Brentuximab Vedotin, Rituximab, and Modified CHP for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) — Patrick Reagan
- Study on Nemtabrutinib for Patients with Difficult-to-Treat Blood Cancers — ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Study Comparing Zilovertamab Vedotin with Standard Treatment for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) — Merck Sharp & Dohme LLC
- Study on Brentuximab Vedotin with Lenalidomide and Rituximab for Treating Relapsed or Hard-to-Treat Diffuse Large B-Cell Lymphoma — Seagen, a wholly owned subsidiary of Pfizer
- Study on Copanlisib and Venetoclax for Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Dana-Farber Cancer Institute
- Study on Emapalumab to Prevent Side Effects from CAR-T Cell Therapy in Non-Hodgkin's Lymphoma Patients — Marcela V. Maus, M.D.,Ph.D.
- Study on the Safety and Effectiveness of KRT-232 with Acalabrutinib for Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia — Kartos Therapeutics, Inc.
- Study on the Safety and Effects of a New Dosing Schedule for Tafasitamab with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Incyte Corporation
- Split-Dose R-CHOP Chemotherapy for Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) — University of Wisconsin, Madison
- Study on IOMAB-ACT and CAR-T Cell Therapy for Patients with Difficult or Returning Diffuse Large B-cell Lymphoma — University of Texas Southwestern Medical Center
- Study Comparing Tafasitamab, Lenalidomide, and R-CHOP with R-CHOP Alone in Newly Diagnosed High-Risk DLBCL Patients — Incyte Corporation
- Study on Adding Venetoclax to Usual Chemotherapy for High-Grade B-Cell Lymphomas — National Cancer Institute (NCI)
- Study on Venetoclax Plus R-ICE Chemotherapy for Difficult or Returning Diffuse Large B-Cell Lymphoma — Molly Gallogly
- Study on Zanubrutinib for Patients with DLBCL and Specific Genetic Mutations or CD5+ — Virginia Commonwealth University
- Study on BGB-16673 for Patients with B-Cell Blood Cancers — BeiGene
- Study Comparing Polatuzumab Vedotin with R-CHP and R-CHOP in Patients with Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- Study of CPI-0209 for Patients with Advanced Solid Tumors and Lymphomas — Constellation Pharmaceuticals
- Study Comparing Epcoritamab and Lenalidomide to Rituximab, Gemcitabine, and Oxaliplatin in Adults with Relapsed or Hard-to-Treat Diffuse Large B-Cell Lymphoma — Genmab
- Study of Zilovertamab Vedotin with Standard Treatment for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) — Merck Sharp & Dohme LLC
- Study on the Safety of Epcoritamab for Adults with Returning or Hard-to-Treat Large B-Cell and Follicular Lymphoma — Genmab
- Study on Epcoritamab with R-CHOP for Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) — Genmab
- Study on Optimizing Cytokine Release Syndrome for Glofitamab with Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Hoffmann-La Roche
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. — Pfizer
- Study on Acalabrutinib Maintenance for Treating Large B-cell Lymphoma — Jonsson Comprehensive Cancer Center
- Study on Acalabrutinib with DA-EPOCH-R or R-CHOP for Untreated Diffuse Large B-cell Lymphoma — National Cancer Institute (NCI)
- Study on Stem Cell Transplant Followed by Polatuzumab Vedotin for B-cell Non-Hodgkin and Hodgkin Lymphoma — New York Medical College
- Study on CAR-20/19-T Cells for Patients with Hard-to-Treat B Cell Cancers — Medical College of Wisconsin
- Preventing CNS Relapse in High-Risk Diffuse Large B-cell Lymphoma with Thiotepa-based Stem Cell Transplant — Washington University School of Medicine
- Study on Itacitinib Before CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — H. Lee Moffitt Cancer Center and Research Institute
- Local Production of CAR T-Cell Therapy for Treating B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia — John Lister
- Study on Mosunetuzumab and Chemotherapy for Untreated High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma with C-Myc Rearrangement — OHSU Knight Cancer Institute
- Study on Obinutuzumab and ICE Chemotherapy for Difficult or Returning CD20+ Non-Hodgkin Lymphoma — New York Medical College
- Study on Pembrolizumab and Chemotherapy for Untreated B Cell Lymphoma — University of Chicago
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, Advanced DLBCL, ALL, and High-Risk LBCL — Novartis Pharmaceuticals
- Study on Polatuzumab Vedotin and Combination Chemotherapy for Treating Untreated Lymphoma — Barbara Ann Karmanos Cancer Institute
- Study on Polatuzumab Vedotin with R-GDP for Treating Relapsed or Hard-to-Treat Diffuse Large B-cell Lymphoma — UNC Lineberger Comprehensive Cancer Center
- Study on Rituximab, Lenalidomide, Acalabrutinib, and Tafasitamab with Chemotherapy for Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma — M.D. Anderson Cancer Center
- Safety and Effectiveness Study of Epcoritamab Combinations for B-cell Non-Hodgkin Lymphoma — Genmab
- Study on Selinexor for Patients with Relapsed or Hard-to-Treat Diffuse Large B-Cell Lymphoma (DLBCL) — Karyopharm Therapeutics Inc
- Study on Selinexor with Chemotherapy for Treating Advanced B Cell Non-Hodgkin Lymphoma — Barbara Ann Karmanos Cancer Institute
- Study on Acalabrutinib and Rituximab for Untreated Elderly and/or Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) — AstraZeneca
- Study on E7777 Before Kymriah for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Masonic Cancer Center, University of Minnesota
- Study of Iopofosine I 131 (CLR 131) for Certain B-Cell Blood Cancers and Waldenstrom Macroglobulinemia — Cellectar Biosciences, Inc.
- Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas — Immunitas Therapeutics
- Study on Subcutaneous Epcoritamab With or Without Lenalidomide as First Treatment for Diffuse Large B-Cell Lymphoma — Genmab
- Study on Zilovertamab Vedotin for Children and Young Adults with Blood Cancers or Solid Tumors — Merck Sharp & Dohme LLC
- Study on Tafasitamab, Retifanlimab, and Rituximab with Standard Therapy for Treating Diffuse Large B-cell Lymphoma — University of Washington
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed or Hard-to-Treat Diffuse Large B-cell Lymphoma — SWOG Cancer Research Network
- Study on Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) for Treating B-cell Lymphoma That Has Returned or Not Improved — National Cancer Institute (NCI)
- Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation — University of Michigan Rogel Cancer Center
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Diffuse Large B Cell Lymphoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.